Press

Press

Corporate Profile

Dystrogen Therapeutics is a clinical-stage life sciences company committed to developing personalized therapies for rare genetic diseases. The company focus on treating patients with rare diseases such as Duchenne muscular dystrophy.
The company was founded based on the pioneering work on chimeric cells therapy for transplantation tolerance, developed by Professor Maria Siemionow MD, PhD, a world renowned scientist and surgeon who led a team of surgeons that performed the first near-total face transplantation in the United States. Our technologies are developed in collaboration with the University of Illinois.

Dystrogen presentation:

  • Dystrogen presentation – Duchenne therapy (pdf)

     

     

    Investor Relations Contacts: investors@dystrogen.com

    Marta Osęka
    Vice President of Business Development and Investor Relations
    oseka@dystrogen.com